PriceTargets.com logo

Oncimmune - ONC Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 28 As of 04/19/2024 02:43 PM ET
▼ -1.1 (-3.78%)

This chart shows the closing price for ONC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oncimmune Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONC

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Oncimmune in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 28.

This chart shows the closing price for ONC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Oncimmune. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/27/2020FinnCapReiterated RatingCorporate
5/21/2020FinnCapReiterated RatingCorporate
5/12/2020FinnCapReiterated RatingCorporate
3/18/2020FinnCapReiterated RatingCorporate
3/4/2020FinnCapReiterated RatingCorporate
2/12/2020FinnCapReiterated RatingCorporate
11/22/2019FinnCapInitiated CoverageCorporateGBX 150
(Data available from 4/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Oncimmune logo
Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.
Read More

Today's Range

Now: GBX 28
Low: 27.50
High: 29

50 Day Range

MA: GBX 21.32
Low: 16.80
High: 30.42

52 Week Range

Now: GBX 28
Low: 13
High: 45

Volume

62,630 shs

Average Volume

76,900 shs

Market Capitalization

£20.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Oncimmune?

The following Wall Street analysts have issued research reports on Oncimmune in the last twelve months:
View the latest analyst ratings for ONC.

What is the current price target for Oncimmune?

0 Wall Street analysts have set twelve-month price targets for Oncimmune in the last year. has the lowest price target set, forecasting a price of £100,000 for Oncimmune in the next year.
View the latest price targets for ONC.

What is the current consensus analyst rating for Oncimmune?

Oncimmune currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ONC.

What other companies compete with Oncimmune?

Other companies that are similar to Oncimmune include SkinBioTherapeutics, Oxford BioDynamics, Destiny Pharma, AorTech International and OptiBiotix Health. Learn More about companies similar to Oncimmune.

How do I contact Oncimmune's investor relations team?

Oncimmune's physical mailing address is Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The company's listed phone number is +44-115-8231869. The official website for Oncimmune is oncimmune.com. Learn More about contacing Oncimmune investor relations.